Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Open accessThe DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [410]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Donepezil, galantamine, and rivastigmine are the cholinesterase inhibitors that are most frequently prescribed [102,103,104,105,106].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This study showed a dose-time-dependent reduction in Aβ plaques and an improvement in clinical manifestations of AD, as assessed by the Clinical Dementia RatingSum of Boxes (CDR-SB) and Mini Mental State Examination (MMSE) scores for the highest dose [20].”
MethodCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 2×
“However, despite the good results obtained in in vivo studies, no improvement in cognitive status, and no reduction of tau in the CSF of patients under treatment was observed [104,105].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“A phase 2 study involving individuals with prodromal AD, and a phase 3 clinical trial studying the efficacy of this treatment at disease onset are currently underway [100,101].”
BackgroundBeneficial effects of physical exercise on neuroplasticity and cognition
Hötting, K., & Röder, B. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.04.005 · Cited by 991
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 3×
“In one phase 3 clinical trial, participants with mild and moderate AD showed good tolerability, but no decrease in cognitive and functional impairment [75].”
BackgroundInfluential
Research works printed but not linked: 3
- Biogen Highlights of Prescribing Information: Aduhelmtm (Aducanumab-Avwa) Injection, for Intravenous Use Initial U.S. Approval: 2021 Biogen Cambridge, MA, USA 2021
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2022 29763201
- Buchanan T. De Bruyn S. Fadini T. Watanabe S. Germani M. Mesa A.B.I.R. A Randomised, Placebo-Controlled, First-in-Human Study with a Central Tau Epitope Antibody–UCB0107 Proceedings of the International Congress of Parkinson’s Disease and Movement Disorders Nice, France 22–26 September 2019
Cited by
Items 101–200 of 237
Saeed, R., Tariq, H. Z., Althobaiti, A., Sadeghian, N., Taslımı, P., al‐Rashida, M., Islam, T., Thabet, H. K., Aftab, H., Şenol, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-32012-y · Cited by 9
Luo, H., Xu, J. L., Huang, D., Chen, Y.-Q., Liu, Y., Li, Y., & Chen, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1030390 · Cited by 10
Stasiak, A., Honkisz-Orzechowska, E., Gajda, Z., Wagner, W., Popiołek-Barczyk, K., Kuder, K., Latacz, G., Juszczak, M., Woźniak, K., Karcz, T. P., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158035 · Cited by 7
Zolkiffly, S. Z. I., Hasan, M. H., Jusoh, S. A., Janakiraman, A. K., Kumar, S. S., Husain, N., Zakaria, Y., & Chellammal, H. S. J. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100547 · Cited by 8
Ge, C., Xu, J., Hu, J., Liu, P., Tang, R., Wang, J., & Ren, H. (2023) · International Conference on Cloud Computing and Big Data Analytics (ICCCBDA) · doi:10.1109/icccbda56900.2023.10154636 · Cited by 6
Discovery of cinnamamide/ester triazole hybrids as potential treatment for Alzheimer’s disease
Tan, L.-J., Lei, W.-J., Liu, M., Cai, Z., Jiang, H., Liu, R., & Li, Z. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107584 · Cited by 7
Memantine suppresses the excitotoxicity but fails to rescue the ataxic phenotype in SCA1 model mice
Belozor, О. S., Vasilev, A., Mileiko, A. G., Mosina, L. D., Mikhailov, I. G., Ox, D. A., Boitsova, E. B., Shuvaev, А. N., Teschemacher, A. G., Kasparov, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116526 · Cited by 5
Decoding the neuroprotective potential of hesperidin: Insights into Alzheimer’s disease
Chauhan, P., Vadia, N., Ballal, S., Joshi, K. K., Maharana, L., Chauhan, A. S., Abomughaid, M. M., Lakhanpal, S., Avinash, D., Thakur, K., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.028 · Cited by 7
Research progress of exosomes used in the Alzheimer's disease treatment
Gao, X., Yang, K., Yuan, X., Song, M., Wang, T., & Shen, C. (2025) · Discover Nano · doi:10.1186/s11671-025-04361-0 · Cited by 6
Symposium: What Does the Microbiome Tell Us about Prevention and Treatment of AD/ADRD?
Capocchi, J. K., Figueroa‐Romero, C., Dunham, S. J. B., Faraci, G., Rothman, J. A., Whiteson, K., Seo, D.-O., Holtzman, D. M., Grabrucker, S., Nolan, Y. M., et al. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1295-24.2024 · Cited by 7
Merighi, S., Nigro, M., Travagli, A., Fernández, M., Vincenzi, F., Varani, K., Pasquini, S., Borea, P. A., Salati, S., Cadossi, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312847 · Cited by 6
The meaning and experience of hope by people living with dementia as expressed through poetry
Amponsem, S., Wolverson, E., & Clarke, C. (2022) · Dementia · doi:10.1177/14713012221137469 · Cited by 5
Understanding the Intricate Role of Exosomes in Pathogenesis of Alzheimer’s Disease
Chauhan, S., Behl, T., Sehgal, A., Singh, S., Sharma, N., Gupta, S., Albratty, M., Najmi, A., Meraya, A. M., & Alhazmi, H. A. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00621-4 · Cited by 6
Rovetta, A., Carosella, L., Arrigoni, F., Vertemara, J., GIOIA, L. D., Zampella, G., & Bertini, L. (2023) · Inorganics · doi:10.3390/inorganics11060227 · Cited by 7
Frontiers of Neurodegenerative Disease Treatment: Targeting Immune Cells in Brain Border Regions
Satyanarayanan, S. K., Han, Z., Xiao, J., Yuan, Q., Yung, W., Ke, Y., Chang, R. C., Zhu, M. H., Su, H., Su, K. P., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.10.007 · Cited by 5
Bhilare, K. D., Dobariya, P., Lee, A., Xie, W., Xie, J., Meints, J. P., Vince, R., Lee, M. K., & More, S. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00382 · Cited by 5
Masum, M. H. U., Lokman, S. M., Parvin, R., Rahman, M. S., Chowdhury, E. H., Chamonara, K., Chowdhury, S., Mahdeen, A. A., & Khatun, M. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326219 · Cited by 4
Effects of Donepezil on the Musculoskeletal System in Female Rats
Londzin, P., Trawczyński, M., Cegieła, U., Czuba, Z. P., & Folwarczna, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108991 · Cited by 6
Yutani, R., Venketaraman, V., & Sheren, N. (2024) · Antioxidants · doi:10.3390/antiox13091106 · Cited by 8
Reactive Oxygen Species in Neurodegenerative Disorders: Mechanisms and Therapeutics
Sharma, A., Tiwari, S., Sharma, H., Pathak, R., & Khan, F. (2025) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-7919-6.ch012 · Cited by 8
LncRNA ENST00000440246.1 Promotes Alzheimer’s Disease Progression by Targeting PP2A
Gao, S., Chang, F., Wang, Y., Yang, W., & Jiang, H. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10552-0 · Cited by 4
Panigrahy, S., Sikder, A., Amulya, E., Shah, S., Khairnar, P., Saraf, S., & Srivastava, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105325 · Cited by 5
New Triazine Derivatives as Serotonin 5-HT6 Receptor Ligands
Łażewska, D., Więcek, M., Satała, G., Chałupnik, P., Żesławska, E., Honkisz-Orzechowska, E., Tarasek, M., Latacz, G., Nitek, W., Szymańska, E., et al. (2023) · Molecules · doi:10.3390/molecules28031108 · Cited by 4
Dias, I., Emmanuel, M., Vogt, P., Guerreiro-Oliveira, C., Melo-Marques, I., Cardoso, S. M., Guedes, R. C., Chaves, S., & Santos, M. A. (2025) · Antioxidants · doi:10.3390/antiox14080921 · Cited by 5
Elecsys CSF AD immunoassays: Sample stability for a new pre‐analytical protocol for fresh CSF
Manuilova, E., Schrurs, I., Rutz, S., McIlwrick, S., Goldhardt, O., Sommer, P., & Grimmer, T. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70797 · Cited by 5
França, F. S., Sperling, L. E., dos Santos, M. G., Teixeira, C. E., de Oliveira, T. F., Türck, P., Belló‐Klein, A., & Pranke, P. H. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-31750-3 · Cited by 6
Bhanja, S. S., Tripathy, S., Mishra, A., Biswal, B., & Sharma, D. K. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2607121 · Cited by 3
Silva, J. G. D. M., Barros, W. D. M., Prado-Lopes, N., & Bellozi, P. M. Q. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111640 · Cited by 3
Combining AI design and molecular dynamics to disrupt amyloid aggregation in Alzheimer’s disease
Esmaeilzadeh, A., Irani, M. A., Javanmard, A., & Khezri, M. G. (2026) · Discover Applied Sciences · doi:10.1007/s42452-026-08245-5 · Cited by 3
Bridging the gaps in alzheimer’s disease: a comprehensive review of current and emerging therapies
Mostafa, R. E., & Asaad, G. F. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02151-3 · Cited by 6
Kandasamy, K., Narasimhamoorthi, S. P., Arulselvan, P., & Jaganathan, D. (2026) · 3 Biotech · doi:10.1007/s13205-026-04763-6 · Cited by 3
Gouvea, R. G., Bezerra, E. S., Amaral, L., da Conceição, R. A., Pauli, F. P., Coutinho, M. S., Amaral, A. A. P., de Oliveira, P. C. O., da Silva., F. D. C., de Souza, A. M. T., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109838 · Cited by 3
Petrov, W., Ślebioda, D., Kozińska, R. B., Kukla, K., Petrov, P., Sroka, M., Tesyna, J., Puźniak, G., Kudliński, M., Rejda, T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135733 · Cited by 6
Current and emerging therapeutic approaches in Alzheimer’s disease
Chauhan, A., Devi, R., Singh, S., Thakur, R., Bhutani, K., Sharma, R., Kumari, A., Kumar, H., Pal, S., & Saini, A. K. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00290-5 · Cited by 4
Alghamdi, A., Bijlsma, M. J., de Vos, S., Schuiling‐Veninga, C. C. M., Bos, J., & Hak, E. (2023) · Pharmaceuticals · doi:10.3390/ph16121694 · Cited by 3
Xu, J.-J., Luo, J., Xi, H., Xu, J., & Wan, L. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1282978 · Cited by 3
Abidar, S., Hriţcu, L., & Nhiri, M. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273309256240702053609 · Cited by 3
Pandey, K., Srivastava, P., Pandey, S. K., Johari, S., Bhatnagar, P., Sonane, M., & Mishra, A. (2024) · Current Molecular Medicine · doi:10.2174/0115665240334785240913071442 · Cited by 4
Kim, H., Cheon, J., Kirindage, K. G. I. S., Jayasinghe, A. M. K., Han, E. J., Park, S.-M., Ahn, G., & Cha, S. (2024) · Algal Research · doi:10.1016/j.algal.2024.103866 · Cited by 5
Proposed Therapeutic Strategy to Combat Alzheimer’s Disease by Targeting Beta and Gamma Secretases
Kumar, D., Anand, P., & Singh, S. K. (2025) · Current Alzheimer Research · doi:10.2174/0115672050380899250602042028 · Cited by 6
Czarnota-Łydka, K., Kucwaj‐Brysz, K., Mordyl, B., Głuch‐Lutwin, M., Karcz, T. P., Jastrzębska‐Więsek, M., Partyka, A., Dąbrowska, M., Satała, G., Sudoł-Tałaj, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118026 · Cited by 3
Li, J., Sun, W., Wang, X., Ding, F., Li, L., Lin, X., & Zhao, Y. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00130 · Cited by 3
Cognitive Impairment in the Primary Care Clinic
Womack, C. L., Perkins, A., & Arnold, J. M. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2024.02.010 · Cited by 4
Kaviyarasu, S., Padmanaban, N., Khute, S., Zengin, G., & Subash, P. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1586728 · Cited by 3
Hatakawa, Y., Tanaka, A., Furubayashi, T., Katsumi, H., Nakamura, R., Konishi, M., Akizawa, T., & Sakane, T. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114661 · Cited by 3
Unraveling the complexity of chronic diseases: an introductory exploration
Prajapati, C., Singh, P., Nand, S., & Singh, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33877-9.00005-7 · Cited by 4
Precision therapeutics for Alzheimer’s disease
Priyanka, S., Manjari, T., Hemalatha, S., Ambika, S., Yilmaz, B. N., Aktürk, B., Arısan, E. D., Kumari, A., & Manojkumar, Y. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.011 · Cited by 2
Therapeutic Potential of Ishige okamurae Yendo as a Multi-Target Inhibitor Against Dementia Symptoms
Kwon, O. Y., & Lee, S. H. (2025) · Life · doi:10.3390/life15111699 · Cited by 2
Dong, Y., Wang, S., Liu, X., Song, Y., Song, Y., & Wang, Y. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00780 · Cited by 4
Das, S. K., Bashir, B., Kolekar, K. A., Harish, V., Patle, D., Vishwas, S., Mittal, N., Jha, S. K., Kumar, P., Gupta, G. K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.103000 · Cited by 4
Raswanthiya, S. P., Fernandes, O. P., Mathew, M. P., Balgote, P. J., & Sivaraman, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11485-8 · Cited by 5
Manoharan, S. D., Usman, A. S., Hamid, H. A., Nassir, C. M. N. C. M., Cheema, M. S., Ramli, M. D. C., Moklas, M. A. M., & Mehat, M. Z. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04702-0 · Cited by 3
Jiang, Z., Qin, Y., Luo, B., Bai, F., Liu, J., Ma, L., He, S., Chen, R., Wang, Y., Liu, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202520239 · Cited by 4
Liu, C., Zhu, Z., Lin, H., Bush, W. S., Jenq, R. R., Cominelli, F., Pillai, J. A., Haines, J. L., Zhu, X., Xu, R., et al. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1735332 · Cited by 2
D’Angiolini, S., Basile, M. S., Mazzon, E., & Gugliandolo, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813924 · Cited by 2
Dhawan, A., Choudhary, S., Gupta, S., Chander, A., & Dhanawat, M. (2023) · Current Drug Therapy · doi:10.2174/1574885519666230913105725 · Cited by 2
Nanotechnology in Drug Delivery: An Overview of Developing the Blood Brain Barrier
Dash, R., Samanta, S., Jena, B. R., & Pradhan, S. (2024) · Current Neurovascular Research · doi:10.2174/0115672026346307240919112023 · Cited by 2
Añazco, T., Werner, T., Torres, M. J., Hornos‐Carneiro, M. F., Fernández, J., Živković, A., Salas, C. O., Castro‐Álvarez, A., Gutiérrez, M., Stark, H., et al. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400387 · Cited by 2
Therapeutic approaches in proteinopathies
Nabi‐Afjadi, M., Dabirmanesh, B., & Uversky, V. N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.008 · Cited by 4
Current Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets
Ranjan, A., Shukla, S., & Singh, S. (2024) · Current Drug Therapy · doi:10.2174/0115748855307998240529063710 · Cited by 1
Proteomic Investigation of Neurotrophic trans-Banglene Reveals Potential Link to Iron Homeostasis
Gunawardana, P. B. W., Gohil, K., Moon, K., Foster, L. J., & Williams, F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04772-1 · Cited by 2
Jung, S., & Park, H. (2025) · Oral Biology Research · doi:10.21851/obr.25.002 · Cited by 1
Peyvand, P., Allami, P., & Rezaei, N. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2025-0025 · Cited by 1
Tolbatov, I., Marzo, T., Peana, M., Medici, S., Zoroddu, M. A., Mendola, D. L., & Marrone, A. (2025) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2025.112979 · Cited by 2
Kheirkhah, F., Hamzehkolaee, M. E., Parvizi, S., Khafri, S., Bijani, A., & Hamzehpour, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04329-y · Cited by 1
Insights into the coaggregation mechanisms of amyloid-α and amyloid-β
Xu, Z., Yan, X., Xia, P., Zhu, Y., Chen, Y., Guo, C., & Li, H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148086 · Cited by 2
Sonwani, A., Pathak, A., & Jain, K. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2576463 · Cited by 1
Young, S. R., Shono, Y., Hauner, K. K. Y., Dworak, E. M., Mansolf, M. A., Curtis, L., Benavente, J. Y., Batio, S., Gershon, R. C., Wolf, M. S., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70219 · Cited by 2
Kim, E. H., Lee, Y., Moon, Y. S., Kwon, O. D., & Kwon, D. R. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1689593 · Cited by 1
Jain, V., & Bharti, S. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.011 · Cited by 2
Dobria, A., Suarez, A. A., Whitmarsh‐Everiss, T., Pavlinov, I., Soliz, V., Hippman, R. S., Petersson, T., Petros, Z. A., & Aldrich, L. N. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00780 · Cited by 1
Ali, N., Alotaibi, F. T., Babu, M. A., Singh, T., Tyagi, Y., Alotaibi, A. N., Bansal, N., & Puri, S. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70220 · Cited by 1
Kherachi, R., Daoud, I., Melkem, N., Chelihi, A., Al‐Shuhaib, M. B. S., Hamouda, S. H. H., Meawad, S. B., El‐Arabey, A. A., & ABDALLA, M. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00605-8 · Cited by 1
Bagul, A. D., Irfan, M., Jaitak, A., Asati, V., Goyal, K., & Monga, V. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70248 · Cited by 2
Phullay, P., Panwar, R., Bajwa, S., Wadhwa, K., Chauhan, P., Pahwa, R., Kriplani, P., Rajak, H., Awasthi, R., & Dureja, H. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00616-z · Cited by 1
Holden, J. M. (2022) · Learning and Motivation · doi:10.1016/j.lmot.2022.101851 · Cited by 1
Mechanism and efficacy of drugs for Alzheimer's disease
Ye, C. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5797 · Cited by 1
Potential Stem Cell Treatment for Alzheimer’s Disease with Possible Applications of Lithium Therapy
Caputo, T. J., Inayat, M. S., & Gallicchio, V. S. (2024) · Journal of Clinical and Laboratory Medicine · doi:10.16966/2572-9578.142 · Cited by 1
Exercise Barriers in Older Individuals with Alzheimer’s Disease: A Cross-Sectional Study
Uysal, İ., Özden, F., Özkeskin, M., Benzer, Z., & Işık, E. İ. (2024) · Medicina · doi:10.3390/medicina60091510 · Cited by 1
Govindaswamy, B., Stephen, K. N., Keerthana, S., Perumal, S., & Thirumurugan, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-4379-0_3 · Cited by 4
Shami, R., Majzoub, R. E., Ismail, A., Kotaich, J., Kassem, M., Safadieh, G., Fayyad‐Kazan, M., & Chahine, B. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2562776 · Cited by 1
Proteomic Investigation of Neurotrophic trans -Banglene Reveals Potential Link to Iron HomeostasisPreprint
Gunawardana, P. B. W., Gohil, K., Moon, K., Foster, L. J., & Williams, F. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.04.611284 · Cited by 1
Cantürk, P. U., & AKÇAM, C. (2023) · Klinik Psikoloji Dergisi · doi:10.57127/kpd.26024438.1262396
Astrocytes Reprogramming for Neurodegenerative Disease Management
Tamegart, L., Hilali, R., Ouaki, H., Rachidi, F., Chakir, I., Ajana, R., Oudghiri, D. E., Draoui, A., Oukhrib, M., Ghachi, H. E., et al. (2023) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-6684-9675-6.ch016
Kaštelan, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042405
Sharma, M., Jain, M., Patil, N., Barnwal, A., Tayade, S., Delta, A. K., Kole, C., & Kaushik, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.21.586063 · Cited by 3
Análise da eficácia clínica do fármaco Aducanumab no tratamento da Doença de Alzheimer
Turke, C. C., Neto, V. C., Zumbano, G. M., Shimada, T., Akamine, M. Y. E., Camargo, R. M., Morelli, S. D. A., & Estrela, H. F. G. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-115
Advances in Developing Small Molecule Drugs for Alzheimer's Disease
Zhang, W., Zhang, L., Lv, M., Fu, Y., Meng, X., Wang, M., & Wang, H. (2024) · Current Alzheimer Research · doi:10.2174/0115672050329828240805074938 · Cited by 1
Epigenomics of neurological disorders
Khorkova, O., & Wahlestedt, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19041-4.00012-1
Neuroprotective Potential of Andrographolide (AG) and its Structural Analogs in Alzheimer’s Disease
Vishnusai, B., Reddy, A. G., Chinnappan, S., Rajangam, J., Sundaramoorthy, A. P., Bhattacharya, V., Mishra, N., Mayasa, V., & Nelson, V. K. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256567124010010
Understanding Alzheimer’s Disease: A Multidisciplinary Perspective
Akbarzadehmoallemkoalei, M., Yektakasmaei, M. P., Tabar, S. S. S., Zolfaghari, K., Noorikoloori, S., Niktalab, P., Rouzrokh, S., Sheykhzadeh, Z., Sanavi, M. A., Dozdouzan, M. A., et al. (2024) · Integrated science · doi:10.1007/978-3-031-72079-6_14 · Cited by 1
Novel Roles of the GPI-Anchor Cleaving Enzyme, GDE2, in Hippocampal Synaptic Morphology and Function
Daudelin, D., Sama-Borbon, D., Zhang, N., & Sockanathan, S. (2025) · eNeuro · doi:10.1523/eneuro.0102-25.2025 · Cited by 2
Formaldehyde, Neuroinflammation, and Cognitive Impairment
Kang, N., Liu, Y., & He, R. (2025) · Springer eBooks · doi:10.1007/978-981-96-7281-3_12
Rashmi, T., Monika, S., & Kumar, N. (2025) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_232_25 · Cited by 1
Emerging Trends in Therapeutic Potential of Curcumin in Alzheimer’s Disease
Bashir, S., Khan, A. S., Gilani, A.-U.-H., & Ahmed, T. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2736-6_6
Lin, J. (2025) · Clinical EEG and Neuroscience · doi:10.1177/15500594251403219 · Cited by 1
DRPMKB1.0: A Comprehensive Knowledge Base for an AI-Oriented Drug Repositioning Prediction Model
Zheng, X., Bi, C., Bo, W., Zhang, Y., Song, J., Du, J., Hu, S., Feng, J., Yang, L., & Shen, B. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01945 · Cited by 1
Metadata
- Authors
- Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L.
- Affiliations
- Instituto Nacional de Gestión Sanitaria (INGESA), Primary Health Care, 51003 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences (Melilla), University of Granada, 52005 Granada, Spain
- Universidad de Sevilla (ES)
- Department of Biomedicine, Biotechnology and Public Health, Physiology Area, Faculty of Medicine, University of Cádiz, Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Biomedicine, Biotechnology and Public Health, Immunology Area, University of Cádiz Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Physiology, Faculty of Health Sciences (Ceuta), University of Granada, 51001 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-05-24
- Volume
- 14
- Issue
- 6
- Pages
- 1117
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9228613
- OpenAlex
- W4281488754
- Cited by
- 239
- References
- 158
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 66 · 2023: 48 · 2022: 11
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- RODIN (Universidad de Cádiz) (submittedVersion, cc-by)
- Funders
- Junta de Andalucía, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- the Ministry of Science and Innovation, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, amyloid-beta, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, aducanumab, donepezil, galantamine, rivastigmine, memantine, gamma-secretase inhibitors, beta-secretase inhibitors, aggregation inhibitors, amyloid-beta clearance, tau aggregation inhibitors, dementia treatment, lifestyle intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.